白介素-17A在肺癌合并胸腔积液中的表达及其临床意义

The Expression of Interleukin-17A in Lung Cancer with Pleural Effusion and Its Clinical Significance

目的:探讨肺癌合并胸腔积液患者血液中白介素-17A(IL-17A)的水平与胸腔灌注疗效及预后的相关性。方法:选取2017年12月—2019年6月我院收治的30例肺癌合并胸腔积液患者以及30例肺癌未合并胸腔积液患者,利用流式液相多重蛋白技术来分别测定患者血液中IL-17A水平。对比两组中IL-17A水平的高低;观察随访30例肺癌合并胸腔积液患者的胸腔灌注疗效及生存情况,通过Kaplan-Merier分析血液IL-17A的水平的高低与患者生存期及生存率的相关性。结果:肺癌合并胸腔积液患者血液中IL-17A的水平高于未合并胸腔积液患者,有显著统计学意义(P<0.01);肺癌合并胸腔积液组Kaplan-Meier输出IL-17A高水平组与低水平组的中位生存期估值分别为5个月和9个月,两组生存曲线整体Log-rank检验结果为P=0.041。结论:肺癌合并胸腔积液患者血液中IL-17A水平的高低与预后密切相关。

Objective:Objective to the correlation between IL-17Alevel of patients with lung cancer combined with pleural effusionand the efficacyof thoracic perfusionand prognosis.Methods:Patients selected between December 2017 and June 2019 with 30 cases of lung cancer combined with pleural effusion and 30 cases of lung cancer combined without pleural effusion.The level of IL-17A in the blood of 60 patients with lung cancer was determined by cytometric bead array.Compared with the levels of IL-17A in the two groups.The efficacy and survival of 30 patients with lung cancer combined with pleural effusion were observed and followed up.The correlation between IL-17A level and survival time and rate was analyzed by Kaplan-Merier.Results:The level of IL-17A of patients with lung cancer combined with pleural effusion was significantly higher than that of patients without pleural effusion(P<0.01).Lung cancer combined with pleural effusion patients the median survival estimates of the blood output group Kaplan-Meier with high IL-17A level and the group with low IL-17A level were 5 months and 9 months respectively,and the Log-rank test result was P=0.041.Conclusion:The level of IL-17A of patients with lung cancer combined with pleural effusion is closely related to the prognosis.